Clinical Trial Update: PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

This update notes an ongoing Phase 1 trial evaluating PVX-410 vaccine with pembrolizumab in patients with HLA-A2+ metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• PVX-410

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Triple Negative Breast Cancer, Metastatic Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING